reports
Novartis breaks ground on flagship manufacturing hub in North Carolina
Novartis breaks ground on flagship manufacturing hub in North Carolina FDA Commissioner Marty Makary, North Carolina Governor Josh Stein and Novartis leadership highlight importance of new hub to US patients and local economyConstruction reflects company’s commitment to ensure end-to-end manufacturing of all key medicines for US patients in the US at scaleGroundbreaking marks continuation of Novartis investment and growth in the US, capping year of significant regulatory and manufacturing milestones East Hanover, December 12, 2025 – Novartis, a leading global innovative medicines company...
- Jean Danjou
- Jean Danjou
- Martial Descoutures
- Martial Descoutures
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expandi...
Press Release: Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseases Qfitlia, the first antithrombin-lowering therapy for hemophilia, can offer consistent protection with as few as six injections a yearCablivi, the first Nanobody medicine, targets acquired/immune-mediated thrombotic thrombocytopenic purpura — a rare, life-threatening blood clotting disorder Paris, December 11, 2025. The National Medical Products Administration (NMPA) in China has approved two innovative Sanofi medi...
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine...
Communiqué de presse : Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia et Cablivi de Sanofi approuvés en Chine, élargissant la prise en charge des maladies rares Qfitlia, premier traitement abaissant le taux d’antithrombine pour le traitement de l’hémophilie, peut offrir une protection constante avec seulement six injections par anCablivi, le premier médicament Nanobody, cible le purpura thrombotique thrombocytopénique acquis/à médiation immunitaire — un trouble rare de la coagulation sanguine potentiellement mortel Paris, le 11 ...
GSK: 1 director
A director at GSK sold 6,000 shares at 1,829p and the significance rating of the trade was 60/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close p...
Press Release: Sanofi completes acquisition of Vicebio
Press Release: Sanofi completes acquisition of Vicebio Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its . This acquisition brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (HMPV), both respiratory viruses, and expands the capabilities in vaccine design and development with Vicebio’s ‘Molecular Clamp’ technology. The acquired vaccine candidate complements Sanofi’s position in respiratory vaccines. It enables Sanofi to offer increased physician and patient choice in...
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio
Communiqué de presse : Sanofi finalise l’acquisition de Vicebio Sanofi finalise l’acquisition de Vicebio Paris, le 4 décembre 2025. Sanofi annonce aujourd’hui la finalisation de . Cette acquisition apporte à Sanofi un candidat-vaccin combiné en phase précoce de développement contre le virus respiratoire syncytial (VRS) et le métapneumovirus humain (HMPV), deux virus respiratoires, et renforce les capacités de conception et de développement de vaccins grâce à la technologie « Molecular Clamp » de Vicebio. Le candidat-vaccin acquis complète la position de Sanofi dans le domaine des vaccins ...
- Dominic Rose
- Naresh Chouhan
Press Release: Sanofi and Regeneron’s Dupixent approved as the first t...
Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite standard-of-care antihistamine treatmentDupixent, which i...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a ...
Communiqué de presse : Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Dupixent, développé par Sanofi et Regeneron, a été approuvé comme étant le premier médicament ciblé dans l’UE depuis plus de dix ans contre l’urticaire chronique spontanée Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years and older living with CSU wh...
Roche Holding AG: 1 director
A director at Roche Holding AG sold 2,000 shares at 315.250CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
- Emira Sagaama
- Rok Stibric
- Emira Sagaama
- Rok Stibric
- Martial Descoutures
- Martial Descoutures
Novartis announces plans to build flagship manufacturing hub in North ...
Novartis announces plans to build flagship manufacturing hub in North Carolina Expansion represents significant investment in North Carolina and is expected to create 700 new jobs in the state by end of 2030Enables manufacturing of medicines across company’s main therapeutic areas in one geographic locationMarks latest milestone in company’s previously announced $23 billion investment in US infrastructure East Hanover, November 19, 2025 – Novartis, a leading global innovative medicines company, today announced plans to expand its operations in North Carolina, creating a new flagship manufa...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.